Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is currently conducting a Phase 3 clinical ...

Key opinion leaders (KOLs) interviewed by GlobalData have expressed the need for therapies with higher efficacy to improve ...

Upadacitinib demonstrated significant efficacy in promoting scalp hair regrowth in severe alopecia areata patients, achieving primary endpoints in nearly half of the participants. The phase 3 trials ...

US pharma major AbbVie recently announced top-line results from one of two parallel studies of the pivotal Phase III UP-AA ...

The UP-AA clinical program includes 2 studies assessing the safety and efficacy of upadacitinib in adults and adolescent patients with severe alopecia areata.

AbbVie released positive topline data from its phase 3 UP-AA trial demonstrating safety and efficacy for upadacitinib for severe alopecia areata in adults and adolescents.“The sudden and ...

On July 30, AbbVie announced positive topline results from Study 2 of its pivotal Phase 3 UP-AA clinical program, which is evaluating the safety and efficacy of upadacitinib (RINVOQ) for treating ...

"AbbVie reports encouraging data from Upadacitinib trial for alopecia areata" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of patients with severe alopecia areata treated ...